The FDA alignment and fresh $30M war chest for their Alzheimer's drug is huge news, but the stock's stuck in a downtrend. 📉 The 9-period EMA is lagging below the 21, and RSI is stuck in the low 40s—nobody's buying the hype yet. Volume is quiet, like the market's waiting for Phase 3 results. This is a classic "show me" story. Until the chart confirms the pipeline optimism, it's a HOLD. #WaitForTheBreakout

Big news is fueling this biotech! 🧠 FDA alignment and fresh $30M for their Alzheimer's drug is the real story. The stock just popped on huge volume, shaking off a sleepy downtrend. RSI is neutral, so no overheat yet. This looks like the start of a new run, not the end. BUY the momentum. #BrainGains

FDA alignment on their Alzheimer's drug is HUGE news, and the chart is finally waking up. 📈 After that brutal sell-off, RSI is climbing out of the oversold ditch. The recent pop on lower volume suggests this could be the calm before the real storm. With a clear regulatory path, this looks like a coiled spring. I'm calling it a BUY. #BiotechBounce

Boom! The FDA just gave Cognition Therapeutics the green light for their Alzheimer's drug, and the market is screaming "YES!" 📈 The stock exploded on massive volume, blasting through resistance. Sure, the RSI is screaming overbought at 88, but this is pure, uncut momentum fueled by legit news. This isn't a fluke; it's a paradigm shift. I'm calling it a BUY on any slight pullback. This rocket has fuel. 🚀 #CGTX